Study Shows Semaglutide Reduces Cardiovascular Events in People With Overweight or Obesity but Not Diabetes

The Brigham was part of a trial that shows for the first time that the weight loss drug semaglutide lowers the incidence of death from cardiovascular causes in those with overweight or obesity but not diabetes. Jorge Plutzky, MD, discusses the findings and implications for clinical care.

Read More...

Inflammation At Least As Important As Cholesterol for Predicting CV Risk in Statin-intolerant Patients

Paul M. Ridker, MD, MPH, of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, and colleagues found inflammation assessed by hsCRP predicted cardiovascular events and death at least as strongly as LDLC when comparing bempedoic acid with placebo in statin-intolerant patients.

Read More...

AI Model Detects Atrial Septal Defects From Electrocardiograms

Shinichi Goto, PhD, at Brigham and Women’s Hospital, and colleagues have developed a deep learning–based model that detects subtle changes in standard 12-lead electrocardiography data to flag patients who should undergo echocardiography to evaluate possible atrial septal defect.

Read More...

The Brigham Keeps Women’s Cardiovascular Health in the Spotlight

The fact that cardiovascular disease is the leading cause of death in women is wildly underappreciated, says the Brigham’s JoAnn E. Manson, MD, MPH, DrPH. Dr. Manson has led many seminal research projects focused on women’s health and set the foundation for related advances at the Brigham today.

Read More...

Initial Decline in eGFR With Dapagliflozin Not Concerning in Patients With Heart Failure and LVEF >40%

Brigham and Women’s Hospital researchers report an initial decline in estimated glomerular filtration rate (eGFR) on initiation of dapagliflozin was not associated with adverse cardiovascular or kidney outcomes and did not appear to alter the long-term trajectory of eGFR decline.

Read More...

Use of Multiple Control Tissue Types Recommended for Molecular Studies of Cerebrovascular Diseases

3d rendered medically accurate illustration of the head anatomy

Researchers at Brigham and Women’s Hospital determined the middle cerebral artery, circle of Willis, and paired superficial temporal artery (STA) are all feasible control vessels for transcriptomic studies of cerebrovascular diseases.

Read More...

Bivalirudin As Efficacious As Heparin During PCI in NSTEMI and Has Better Safety Profile

Brigham and Women’s Hospital researchers conducted a patient-level meta-analysis of ACUITY plus four other large randomized trials. Bivalirudin was not associated with any significant difference in 30-day effectiveness outcomes compared with heparin, but had a substantially better safety profile.

Read More...

Comprehensive Study Categorizes Economic Consequences of Stroke on the Global, Regional and Country Levels

Researchers at Brigham and Women’s Hospital recently completed the first study that assessed the macroeconomic consequences of stroke and its subtypes globally in a standardized way.

Read More...

New TIMI Risk Score Provides Individualized CV Risk Profile for Patients With Type 2 Diabetes

Using contemporary data sets reflecting current clinical practices, researchers at Brigham and Women’s Hospital developed the TIMI Risk Score for Atherothrombosis in Diabetes, which uses information readily available from the medical chart to predict atherothrombotic complications in patients with type 2 diabetes.

Read More...

Brigham Heart & Vascular Faculty at AHA Scientific Sessions 2023

Audience Full of People in Dark Conference Hall Watching Keynote Presentation

On November 11—13, 2023, experts from the Brigham’s Heart and Vascular Center will join thousands of colleagues in raising awareness and improving cardiovascular health at this year’s American Heart Association (AHA) Scientific Sessions.

Read More...